Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors

References

• Rind D, Walton S, Agboola F, et al. Valoctocogene roxaparvovec and emicizumab for hemophilia A: effectiveness and value; evidence report. Inst Clin Econ Rev. 2020.
   Google Scholar
• Lyons J, Desai V, Xu Y, et al. Development and validation of an algorithm for identifying patients with hemophilia a in an administrative claims database. Value Health. 2018;21(9):1098–1103.
   PubMed Web of Science ®Google Scholar
• Data & Statistics | Hemophilia | NCBDDD |. Centers for Disease Control and Prevention, September 2020. [cited March 2021]. Available from: https://www.cdc.gov/ncbddd/hemophilia/data.html
   Google Scholar
• Simpson ML, Valentino LA. Management of joint bleeding in hemophilia. Expert Rev Hematol. 2012;5(4):459–468.
   PubMed Web of Science ®Google Scholar
• Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia a and B. Blood Coagul Fibrinolysis. 2020;31(3):186–192.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158.
   PubMed Web of Science ®Google Scholar
• Hemophilia A. Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. [cited 2021 March]. Available from: https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a#ref_5891
   Google Scholar
• Treatment of Hemophilia. Centers for Disease control and Prevention. [cited 2021 March]. Available from: https://www.cdc.gov/ncbddd/hemophilia/treatment.html
   Google Scholar
• Aledort L, Mannucci PM, Schramm W, et al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion. 2019;17(6):479.
   PubMed Web of Science ®Google Scholar
• Powell K, Williams A, Sheen J, et al. Uptake of Emicizumab-kxwh (Hemlibra) in the MO HealthNet population and impact on medical and pharmacy cost and utilization. Poster presented at: the AMCP eLearning Days, 2020 April 20–24.
   Google Scholar
• Ebbert PT, Xavier F, Seaman CD, et al. Emicizumab prophylaxis in patients with haemophilia a with and without inhibitors. Haemophilia. 2020;26(1):41–46.
   PubMed Web of Science ®Google Scholar
• Hemlibra (emicizumab). Roche. 2022. Available from: https://www.roche.com/media/releases/med-cor-2017-11-16
   Google Scholar
• IBM. IBM MarketScan research databases. [cited 2022 June 6]. Available from: https://www.ibm.com/in-en/products/marketscan-research-databases/databases
   Google Scholar
• Srivastava A, Brewer AK, Mauser‐Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47.
   Web of Science ®Google Scholar
• Fryar CD, Kruszon-Moran D, Gu Q, et al. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. Natl Health Stat Report. 2018;122:1–16.
   Google Scholar
• Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for disease control and prevention 2000 growth charts for the United States: improvements to the 1977 national center for health statistics version. Pediatrics. 2002;109(1):45–60.
   PubMed Web of Science ®Google Scholar
• Shrestha A, Eldar‐Lissai A, Hou N, et al. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–e275.
   PubMed Web of Science ®Google Scholar
• Su J, Zhou J, Buckley B, et al. The immune tolerance induction factor utilizations and costs for the management of male hemophilia-A patients who developed inhibitors. Blood. 2016;128(22):4758–4758.
   Google Scholar
• Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7(1):105–125.
   PubMed Web of Science ®Google Scholar
• Shelby Livingston. Medicare, Medicaid contain costs better than private insurers, study says. 11 February 2019. [cited 2019 May 1]. Available from: https://www.modernhealthcare.com/article/20190211/NEWS/190219996/medicare-medicaid-contain-costs-better-than-private-insurers-study-says.
   Google Scholar
• Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia a patients treated with emicizumab. J Clin Med. 2021;10(19):4303.
   PubMed Web of Science ®Google Scholar
• Barg AA, Avishai E, Budnik I, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia a and inhibitors—a single‐center cohort. Pediatr Blood Cancer. 2019;66(11):e27886.
   PubMed Web of Science ®Google Scholar
• Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real‐world data. Br J Haematol. 2020;191(2):282–290.
   PubMed Web of Science ®Google Scholar
• Barg AA, Budnik I, Avishai E, et al. Emicizumab prophylaxis: prospective longitudinal real‐world follow‐up and monitoring. Haemophilia. 2021;27(3):383–391.
   PubMed Web of Science ®Google Scholar
• Misgav M, Brutman‐Barazani T, Budnik I, et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real‐world data. Haemophilia. 2021;27(2):253–260.
   PubMed Web of Science ®Google Scholar
• Lewandowska M, Randall N, Bakeer N, et al. Management of people with haemophilia a undergoing surgery while receiving emicizumab prophylaxis: real‐world experience from a large comprehensive treatment Centre in the US. Haemophilia. 2021;27(1):90–99.
   PubMed Web of Science ®Google Scholar
• Caplan EO, Patel AM, DeClue RW, et al. Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia a by age. J Comp Eff Res. 2021;10(15):1121–1131.
   PubMed Web of Science ®Google Scholar
• Batt K, Schultz BG, Caicedo J, et al. A real-world study of pre-post annualized bleed rates and all cause costs among non-inhibitor patients with hemophilia a switching from FVIII prophylaxis to emicizumab. Blood. 2021;138(Supplement 1):3028–3028.
   Google Scholar
• McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with hemophilia with and without inhibitors. Blood. 2019;134(Supplement_1):1137–1137.
   Google Scholar
• Samelson‐Jones BJ, Guelcher C, Kuhn J, et al. Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021;27(4):591–598.
   PubMed Web of Science ®Google Scholar
• Cafuir L, Estrin A, Chen E, et al. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with hemophilia a without inhibitors. J Med Econ. 2022;25(1):984–992.
   PubMed Web of Science ®Google Scholar